Viking Therapeutics Inc (VKTX) — Quality & forensics

As of 2026-09-21 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

27 /100 composite · 6 modules · general weight set

Quality 1
Growth 24
Balance sheet 63
Cash quality 44
Capital allocation 14
Momentum 30

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

24.94 Altman Z-Score

Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

1/7 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

Continue: the VKTX chart & overview · the earnings record

FAQ · from the current data · as of 2026-09-21

Quick answers

What is Viking Therapeutics Inc's Closelook quality reading?

The composite reads 27/100 across 6 modules, as of 2026-09-21: quality 1, growth 24, balance sheet 63, cash quality 44, capital allocation 14, momentum 30. Closelook scores are research diary readings, not ratings or investment advice.

What is Viking Therapeutics Inc's Altman Z-Score?

24.94, which sits in the safe zone (above 2.99) as of 2026-09-21. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Viking Therapeutics Inc's Piotroski F-Score?

1 of 7, as of 2026-09-21. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

Related in the Closelook universe

same Closelook index seat first, then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.